The current study explores the utility of GASP-1 through immunohistochemistry (IHC) and enzyme-linked immunosorbent assay (ELISA) analyses, revealing a 5-fold difference in serum GASP-1 levels between benign prostatic hyperplasia (BPH) and PCa patients. This evidence concerns the gene GPRASP1 and benign prostatic hyperplasia.